CHOP Regimen — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase4	Phase 4	13	22	—	—	1993-01
Non-Hodgkin Lymphoma	Phase4	Phase 4	0	4	—	—	2011-08
Leukemia	Phase2	Phase 2	0	1	—	—	2002-06

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 17 hours ago

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT3 Fusion1
CHOP Regimen	Myeloid/Lymphoid Neoplasm

Clinical trials

Trials with this intervention (22)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–22 of 22 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00004112	Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma	completed	Phase 3	—	University of NebraskaOTHER	1	Sep 23, 2024	clinicaltrials
NCT05963347	Go-CHOP as the Frontline Therapy for PTCL	unknown	Phase 2	45